Mayo Foundation for Medical Education and Research

Candace Y W Lee

John C Burnett, Jr

John Burnett

This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

Natriuretic polypeptides

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.

Nucleic acids encoding for chimeric natriuretic polypeptides with unique pharmacologic profiles

Method of increasing natriuretic activity by administering natriuretic polypeptides with unique pharmacologic profiles

Method of treatment of cardiovascular or renal conditions with natriuretic polypeptides with unique pharmacologic profiles

Chimeric natriuretic polypeptides with unique pharmacologic profiles

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.

Growing community of inventors

Dollard-des-Ormeaux, Canada

Candace Y W Lee